Literature DB >> 11740807

Bone marrow angiogenesis in patients with active multiple myeloma.

A Vacca1, D Ribatti, A M Roccaro, A Frigeri, F Dammacco.   

Abstract

Factor VIII-related antigen (FVIII-RA)-positive microvessel areas were measured by both immunohistochemistry and computerized image analysis in patients with active multiple myeloma (MM), nonactive MM, and monoclonal gammopathies of undetermined significance (MGUS). A five-to sixfold larger area was found in patients with active MM compared to the other two groups. Aquaporin 1 (AQP1)-positive microvessel areas, measured with the same techniques on adjacent tissue sections, were also increased in active MM, and tended to be larger than and closely correlated with the FVIII-RA areas. Numerous mast cells were found in the bone marrow of active MM patients, and counts were strictly correlated with the microvessel density. The conditioned medium (CM) of bone marrow plasma cells from active MM patients stimulated endothelial cell proliferation and chemotaxis, monocyte chemotaxis, and angiogenesis in vivo (assessed by the chick embryo chorioallantoic membrane [CAM] system) more strongly and frequently than the CM of patients with nonactive MM and MGUS. Immunoassay of plasma cell lysates gave significantly higher levels of fibroblast growth factor-2 (FGF-2) in patients with active MM than in the other two groups, and a neutralizing anti-FGF-2 antibody inhibited by 46% to 68% the biological activity exerted by the CM in vitro and in the CAM. In situ hybridization of bone marrow plasma cells and zymography of CM showed that patients with active MM express higher levels of matrix metalloproteinase-2 (MMP-2) mRNA and protein than those with nonactive MM and MGUS, whereas MMP-9 expression and secretion overlapped in all groups. Overall data indicate that patients with active MM represent the vascular phase of plasma cell tumors that is induced, at least partly, through FGF-2 and MMP-2. Mast cells possibly contribute to the vascular phase via angiogenic factors in their secretory granules. Both angiogenesis and MMP-2 secretion can account for intramedullary and extramedullary spreading of plasma cells in patients with active MM. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740807     DOI: 10.1016/s0093-7754(01)90022-3

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  17 in total

1.  Brain-derived neurotrophic factor induces proliferation, migration, and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K/AKT signaling.

Authors:  Chun-yan Sun; Yu Hu; Jing Huang; Zhang-bo Chu; Lu Zhang; Xiao-mei She; Lei Chen
Journal:  Tumour Biol       Date:  2010-02-11

2.  Bone marrow angiogenesis and progression in multiple myeloma.

Authors:  Roberto Ria; Antonia Reale; Annunziata De Luisi; Arianna Ferrucci; Michele Moschetta; Angelo Vacca
Journal:  Am J Blood Res       Date:  2011-06-08

3.  Lack of Aquaporin 9 Reduces Brain Angiogenesis and Exaggerates Neuronal Loss in the Hippocampus Following Intracranial Hemorrhage in Mice.

Authors:  Weiyang Ji; Jing Wang; Jie Xu; Xudong Zhao; Xing Xu; Xiaojie Lu
Journal:  J Mol Neurosci       Date:  2016-11-24       Impact factor: 3.444

4.  Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma.

Authors:  Suyun Wang; Zhiyong Cheng; Xiaoyang Yang; Kai Deng; Yan Cao; Hao Chen; Ling Pan
Journal:  Int J Hematol       Date:  2010-06-26       Impact factor: 2.490

5.  Curing myeloma at last: defining criteria and providing the evidence.

Authors:  Bart Barlogie; Alan Mitchell; Frits van Rhee; Joshua Epstein; Gareth J Morgan; John Crowley
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

6.  Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors.

Authors:  Takayuki Nakayama; Lei Yao; Giovanna Tosato
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

7.  Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial.

Authors:  M Bhutani; B Turkbey; E Tan; T J Kemp; L A Pinto; A R Berg; N Korde; A R Minter; B M Weiss; E Mena; L Lindenberg; O Aras; M P Purdue; J N Hofmann; S M Steinberg; K R Calvo; P L Choyke; I Maric; K Kurdziel; O Landgren
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

8.  Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation.

Authors:  Huei-Chen Lao; Jacqueline K Akunda; Kyung-Soo Chun; Gordon P Flake; Stuart H Yuspa; Robert Langenbach
Journal:  Carcinogenesis       Date:  2012-08-17       Impact factor: 4.944

9.  3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.

Authors:  Pilar de la Puente; Barbara Muz; Rebecca C Gilson; Feda Azab; Micah Luderer; Justin King; Samuel Achilefu; Ravi Vij; Abdel Kareem Azab
Journal:  Biomaterials       Date:  2015-09-12       Impact factor: 12.479

10.  piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma.

Authors:  H Yan; Q-L Wu; C-Y Sun; L-S Ai; J Deng; L Zhang; L Chen; Z-B Chu; B Tang; K Wang; X-F Wu; J Xu; Y Hu
Journal:  Leukemia       Date:  2014-04-15       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.